Mebendazole Polymorph C Formulation for Brain Tumor Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapeutics, especially for central nervous system (CNS) cancers, face challenges due to the blood-brain barrier (BBB) limiting the effectiveness of systemically administered drugs, with only about 2% of small-molecule drugs able to cross, and mebendazole's hydrophobic nature and polymorphic forms complicating its brain penetration and pharmacokinetics, necessitating a more effective and consistent formulation.
Innovation Solution
A pharmaceutical formulation comprising at least 90% mebendazole polymorph C, granulated for enhanced bioavailability and stability, combined with a method to monitor the polymorph composition using infrared spectroscopy, and potentially paired with P-glycoprotein inhibitors like elacridar to improve brain penetration and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If mebendazole is administered systemically to treat CNS cancers, then the drug can reach the bloodstream, but the blood-brain barrier blocks most of the drug from penetrating into the brain tissue
Solution Approach 1:
The patent changes the physical-chemical parameters of mebendazole by isolating and using a specific polymorph form (polymorph C) with distinct solubility and pharmacokinetic properties. This polymorph form achieves superior brain penetration and maintains higher drug concentrations in brain tissue compared to other polymorph forms, thereby overcoming the blood-brain barrier limitation.
Solution Approach 2:
The patent employs P-glycoprotein inhibitors (such as elacridar) as intermediary substances that block the efflux transport mechanism at the blood-brain barrier. These inhibitors prevent the active pumping of mebendazole out of the brain, thereby enhancing and maintaining drug concentrations in the central nervous system tissue.
2Reliability
If mebendazole is formulated to improve brain penetration, then therapeutic efficacy increases, but polymorph transformation reduces consistency and reliability
Solution Approach 1:
The patent extracts and isolates the specific active polymorph form (polymorph C) from the mixture of polymorphs. By preparing formulations containing predominantly this single polymorph form and using identification methods to verify its presence, the patent ensures consistent pharmacokinetic behavior and therapeutic efficacy while eliminating the variability caused by polymorph transformation.
3Quantity of substance
If mebendazole polymorph C is used to maximize efficacy, then brain penetration improves, but manufacturing and quality control become more complex
Solution Approach 1:
The patent replaces complex analytical instrumentation with a simplified infrared spectroscopy method for identifying and verifying the presence of polymorph C in formulations. This spectroscopic approach provides a rapid, reliable, and accessible means of quality control that does not require sophisticated equipment, thereby reducing manufacturing complexity while ensuring polymorph consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant brain concentrations and improved therapeutic efficacy for CNS cancers, with polymorph C demonstrating superior potency and stability, and the combination with elacridar enhancing survival benefits in glioma and medulloblastoma models, while maintaining safety.
Implementation Method 1
the step of assaying comprises infrared spectroscopy
Data Source
Figure 1A~1E
Figure 2A~2F
Figure 3A~3D
AI summary
Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.